Table 2.

Changes of IMA content in serum of patients with cardiovascular diseases.

Pathology		Age, years	No of examined	IMA value		Combination with other markers and sensitivity	Ref.
				Control	Patients
Acute coronary syndrome	NSTEMI STEMI UA	62.32 ± 16.63	n = 50	0.410 ± 0.081 ABSU	0.925 ± 0.094 ABSU 0.843 ± 0.146 ABSU 0.783 ± 0.221 ABSU	cTnI, CK-MB, ECG 92-94%	[79]
	NSTEMI STEMI UA	—	n = 135	54.70 ± 17.29 U/mL	87.31 ± 5.95 U/mL 92.10 ± 10.60 U/mL 88.90 ± 6.16 U/mL	cTnI, CK-MB 88%	[80]
Acute aortic dissection		53 ± 7	n = 98	0.62 ± 0.18 ABSU	0.70 ± 0.13 ABSU	cTnT, CK-MB 84.7%∗	[84]
		52.99 ± 12.17	n = 731	—	74.66 ± 20.84 U/mL	IMA–independent forecaster for in-hospital mortality	[85]
Chronic heart failure		68 ± 7	n = 59	0.379 ± 0.08 ABSU	0.894 ± 0.23 ABSU	cTnI, NT-proBNP 92.9%∗	[87]
		70 ± 11	n = 55	0.470 ± 0.1 ABSU	0.669 ± 0.2 ABSU	Total antioxidant status, total oxidant status, oxidative stress index–not correlation	[88]
Dilated cardiomyopathy		46 ± 14	n = 42	93.9 ± 9.9 (76-122) kU/L	89.9 ± 13.1 (71-117) kU/L	cTnI, CK-MB, CPK, NT-proBNP, total protein, albumin Not significance	[89]
		56 (range 35-68)	n = 152	Prechemotherapy 59.2 ± 10.9 U/mL	After the sixth cycle of chemotherapy 140.1 ± 14.8 U/mL	cTnT, CK-MB 92%	[90]

Note: IMA was measured in serum by ACB assay. ^∗ = sensitivity for IMA alone; ABSU: absorbance units; U: units; CPK: creatine phosphokinase; CK-MB: creatine kinase MB; cTn: cardiac troponin; ECG: electrocardiogram; NSTEMI: non-ST-segment elevation myocardial infarction; STEMI: ST-segment elevation myocardial infarction; NT-proBNP: N-terminal prohormone of brain natriuretic peptide; UA: unstable angina.